Evelyna Derhovanessian

Evelyna Derhovanessian leads clinical biomarker strategy at BioNTech, developing comprehensive immune monitoring platforms to characterize the T cell responses induced by mRNA cancer vaccines and identify correlates of clinical efficacy. Her work on high-throughput T cell assays has enabled the detailed characterization of neoantigen-specific immune responses in cancer vaccine trial participants. She has contributed to establishing the immunological evidence that mRNA cancer vaccines can generate de novo T cell responses against previously unrecognized tumor neoantigens.